Related references
Note: Only part of the references are listed.Cytoreductive treatment strategies for de novo metastatic prostate cancer
Martin J. Connor et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
Frederik B. Thomsen et al.
PLOS ONE (2020)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients
Cem Onal et al.
CLINICAL NUCLEAR MEDICINE (2019)
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Thomas B. L. Lam et al.
EUROPEAN UROLOGY (2019)
Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer
O. P. Singh et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2019)
68Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer
George Hruby et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy
Yasutaka Yamada et al.
ASIAN JOURNAL OF ANDROLOGY (2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2018)
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
J. Stranne et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2018)
When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
Yiwei Lin et al.
BMC UROLOGY (2017)
Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy? A Population-based Study
Yaacov R. Lawrence et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL
Mann Ang et al.
BJU INTERNATIONAL (2016)
Current use of PSMA - PET in prostate cancer management
Tobias Maurer et al.
NATURE REVIEWS UROLOGY (2016)
Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?
Tobias Maurer et al.
INTERNATIONAL JOURNAL OF UROLOGY (2014)
Treatment Outcomes in Non-Metastatic Prostate Cancer Patients With Ultra-High Prostate-Specific Antigen
Patricia Tai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
Koramadai Karuppusamy Kamaleshwaran et al.
INDIAN JOURNAL OF NUCLEAR MEDICINE (2012)
Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?
Jee Young Jang et al.
KOREAN JOURNAL OF UROLOGY (2012)
IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS
George Rodrigues et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Anders Widmark et al.
LANCET (2009)
Systemic endocrine instigation of indolent tumor growth requires osteopontin
Sandra S. McAllister et al.
CELL (2008)
Share Paper
